What is the recommended management for localized and metastatic prostate cancer?

Management of Localized and Metastatic Prostate Cancer

Localized Disease Management

For localized prostate cancer, management is risk-stratified, with active surveillance strongly recommended for very low and low-risk disease, while intermediate and high-risk disease requires definitive treatment with either radical prostatectomy or radiotherapy combined with androgen deprivation therapy (ADT). 1

Risk Stratification Framework

Patients must be classified into risk categories to guide treatment decisions 2:

• Very Low/Low Risk: PSA <10, Gleason Grade Group 1 (Gleason 3+3), limited tumor burden
• Favorable Intermediate Risk: Grade Group 2 (Gleason 3+4) with PSA <10
• Unfavorable Intermediate Risk: Grade Group 2 with PSA 10-20, or Grade Group 3 (Gleason 4+3) with PSA <20
• High Risk: PSA >20, Grade Group 4-5 (Gleason 8-10), or clinical stage ≥T3

Treatment by Risk Category

Very Low and Low Risk Disease:

• Active surveillance is the recommended first-line approach 1
• Metastatic staging with CT/bone scan is NOT indicated 1
• Alternative curative options include radical prostatectomy, external beam radiotherapy, or brachytherapy 2, 3
• Watchful waiting (with delayed hormone therapy only if symptomatic) is appropriate for men unsuitable for curative treatment 2

Favorable Intermediate Risk:

• Radical prostatectomy or radiotherapy (external beam or brachytherapy, alone or combined) 2, 3
• Active surveillance may be considered in select cases 2
• Staging for metastases using MRI/CT (abdomen/pelvis) and bone scan 2

Unfavorable Intermediate Risk:

• Radical prostatectomy with pelvic lymphadenectomy 3
• OR radiotherapy with consideration of short-term (4-6 months) neoadjuvant ADT 2, 4
• Staging for metastases is mandatory 2

High Risk and Locally Advanced Disease:

• Long-term ADT (24-36 months) plus radical radiotherapy is the standard of care 2, 3, 4
• Staging must include CT chest/abdomen/pelvis and bone scan 2
• Alternative: Radical prostatectomy with extended pelvic lymphadenectomy (though radiotherapy + ADT has stronger evidence) 2
• Neoadjuvant docetaxel may be considered 2

Critical Counseling Points

Patients must understand that treatment causes sexual dysfunction, infertility, and urinary/bowel problems 2. Consultation with both a urologist and radiation oncologist is strongly recommended before treatment decisions 1. ADT with radiation increases severity of sexual dysfunction and causes systemic side effects including fatigue, metabolic changes, and bone loss 3.

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

For metastatic hormone-sensitive disease, ADT alone is obsolete—treatment intensification with ADT plus either abiraterone, enzalutamide, apalutamide, or docetaxel is now the standard of care. 5

First-Line Treatment Options (Choose ONE combination):

ADT + Abiraterone (1000 mg daily) + Prednisone (5 mg daily):

• Strong recommendation for high-risk disease (per LATITUDE criteria: ≥2 of visceral metastases, ≥3 bone lesions, Gleason ≥8) 5
• Moderate recommendation for low-risk disease (per STAMPEDE) 5

ADT + Enzalutamide (160 mg daily):

• Strong recommendation for all metastatic patients, including those with prior local therapy 5
• Demonstrated survival benefits across disease volumes 5

ADT + Apalutamide (240 mg daily):

• Strong recommendation for all metastatic patients 5
• Consistent benefits except in prior docetaxel subgroup (where benefit is less certain) 5

ADT + Docetaxel (6 cycles):

• Recommended for fit patients who can tolerate chemotherapy 2, 5
• Shorter treatment course with lower financial burden than ARTAs 5
• Particularly appropriate when cost is a major concern

ADT Alone:

• Reserved ONLY for frail patients who cannot tolerate intensified therapy 2

Additional Considerations:

• Bone health agents (denosumab or zoledronate) should be added for patients with bone metastases 4
• Radiotherapy to the primary tumor may be considered for low-volume disease 2

Non-Metastatic Castration-Resistant Prostate Cancer (M0 CRPC)

For high-risk M0 CRPC (PSA doubling time <10 months), continue ADT and add apalutamide, darolutamide, or enzalutamide. 2

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Continue ADT throughout all subsequent lines of therapy. 6

First-Line mCRPC (Choose ONE):

• Abiraterone + prednisone 2, 4
• Enzalutamide 2, 4
• Docetaxel chemotherapy 2, 4
• Radium-223 (ONLY for bone-predominant disease without visceral metastases in symptomatic patients) 2, 4

Second-Line and Beyond:

• Cabazitaxel (post-docetaxel) 2, 4
• Alternative ARTA if not previously used 2
• Radium-223 for bone-only disease 2
• PARP inhibitors for patients with DNA repair mutations 7
• PSMA-targeted therapy in appropriate candidates 7

Common Pitfalls to Avoid

1. Do NOT use ADT monotherapy for metastatic hormone-sensitive disease unless the patient is truly too frail for combination therapy—this is substandard care 5

2. Do NOT deny radical local treatment to patients with localized disease on conventional imaging just because novel imaging (PSMA-PET) shows oligometastatic lesions 2

3. Do NOT use primary ADT alone for non-metastatic disease—it is not recommended as standard initial treatment 4

4. Do NOT perform routine CT or bone scans for very low or low-risk disease—this leads to overtreatment 1

5. Do NOT forget to counsel about sexual, urinary, and bowel dysfunction before any definitive treatment 2, 3

6. Do NOT use short-term ADT (4-6 months) for high-risk disease receiving radiotherapy—24-36 months is required 3, 4